160 related articles for article (PubMed ID: 29053909)
1. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.
Younossi ZM; Chan HLY; Dan YY; Lee MH; Lim YS; Kruger E; Tan SC
J Viral Hepat; 2018 Mar; 25(3):228-235. PubMed ID: 29053909
[TBL] [Abstract][Full Text] [Related]
2. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
Younossi Z; Brown A; Buti M; Fagiuoli S; Mauss S; Rosenberg W; Serfaty L; Srivastava A; Smith N; Stepanova M; Beckerman R
J Viral Hepat; 2016 Mar; 23(3):217-26. PubMed ID: 26482680
[TBL] [Abstract][Full Text] [Related]
3. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
Younossi ZM; Jiang Y; Smith NJ; Stepanova M; Beckerman R
Hepatology; 2015 May; 61(5):1471-8. PubMed ID: 25706754
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Tapper EB; Bacon BR; Curry MP; Dieterich DT; Flamm SL; Guest LE; Kowdley KV; Lee Y; Tsai NC; Younossi ZM; Afdhal NH
J Viral Hepat; 2017 Jan; 24(1):22-27. PubMed ID: 27730717
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
10. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
[TBL] [Abstract][Full Text] [Related]
13. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Hsu SJ; Enkhzaya S; Lin YY; Tseng TC; Khosbayar T; Tsai CH; Wang TS; Enkhtuya D; Ivshinkhorol D; Naranzul N; Jargalsaikhan B; Amarsanaa J; Baatarkhuu O; Kao JH
J Formos Med Assoc; 2020 Mar; 119(3):712-719. PubMed ID: 31672433
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
15. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
Nguyen MH; Trinh H; Do S; Nguyen T; Nguyen P; Henry L
Am J Gastroenterol; 2017 Dec; 112(12):1824-1831. PubMed ID: 29087397
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.
Chen JJ; Lee PL; Chiu HC; Tung HD; Chiu YC; Cheng PN
J Gastroenterol Hepatol; 2020 Mar; 35(3):467-472. PubMed ID: 31445507
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
